原发性胆汁性肝硬化患者对UDCA治疗的生化应答标准被引量：2

下载PDF

导出

摘要原发性胆汁性肝硬化（PBC）是一种慢性肝内胆汁淤积性疾病，其发病机制与自身免疫有关。该病多见于中年女性，临床症状主要表现为乏力、瘙痒，实验室检查以碱性磷酸酶（ALP）、谷氨酰转肽酶（GGT）升高为主，血清学可见特异性抗线粒体抗体2型（AMA—M2）阳性，病理特征为慢性非化脓性胆管炎，主要累及小叶间隔及间隔胆管。熊去氧胆酸（UDCA）是目前唯一被美国食品及药品监督管理局批准的用于PBC治疗的药物。多项研究报道UDCA治疗可以改善PBC患者的生化指标，但能否改善组织学、远期生存率及降低肝移植需求尚无统一结论”。近几年研究结果显示，UDCA治疗生化应答良好的患者生存率明显高于应答欠佳者。

作者宋宁贾继东

机构地区首都医科大学附属北京友谊医院肝病中心

出处《肝脏》 2013年第8期564-565,共2页 Chinese Hepatology

基金首都医科大学附属北京友谊医院肝病中心(100050)

关键词原发性胆汁性肝硬化肝硬化患者生化应答 UDCA 治疗化脓性胆管炎药品监督管理局远期生存率

分类号 R575.2 [医药卫生—消化系统]

引文网络
相关文献

参考文献19

1landor KD, Gershwin ME, Poupon R, et al. Primary biliary cir rhosis. Hepatology, 2009, 50: 291-308.
2Gong Y, Huang Z, Christensen E, et al. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic re view and meta analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol, 2007, 102: 1799- 1807.
3Kuiper EM, Hansen BE, Lesterhuis W, et al. The long term effect of ursodeoxycholic acid on laboratory liver parameters in bio- chemically non-advanced primary biliary cirrhosis. Clin Res Hepa- tol Gastroenterol, 2011, 35:29- 33.
4Poupon RE, Lindor KD, Cauch Dudek K, et al. Combined analy sis of randomized controlled trials of ursodeoxycholic acid in prima- ry biliary cirrhosis. Gastroenterology, 1997, 113: 884-890.
5Shi J, Wu C, Lin Y, et al. Long term effects of mid dose ursode oxycholic acid in primary biliary cirrhosis: a meta analysis of ran domized controlled trials. Am J Gastroenterol, 2006, 1111 : 1529- 1538.
6Azemoto N, Kumagi T, Abe M, et al. Biochemical response to ur- sodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res, 2011, 41: 310- 317.
7Corpechot C, Abenavoli L, Rabahi N, et al. Biochemical response to ursodeoxycholic acid and long term prognosis in primary biliary cirrhosis. Hepatology, 2008, 48: 871-877.
8Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis ; biochemical response to treatment and prediction of long term outcome. J Hepatol, 2011, 55; 1361 -1367.
9Kuiper EM, Hansen BE, de Vries RA, et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology, 2009, 136: 1281-1287.
10Pares A, Caballeria I., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology, 2006, 130:715- 720.